Biophage Pharma reports net loss of C$239,779 for the quarter

By Lisa Kerner

Charlotte, N.C., Oct. 31 - Biophage Pharma Inc. said its third quarter ended Aug. 31 showed a net loss of C$239,779, or C$0.01 loss per share, compared to a net loss of C$165,973, or C$0.00 per share, for the prior-year period.

The company's revenues for the quarter totaled C$185,809, up slightly from C$185,548 for the same period in 2005.

Research and development costs for the quarter were down 28% at C$85,754, from C$118,582 for the third-quarter 2005.

Biophage had cash and cash equivalents of C$455,380 at Aug. 31, compared to C$187,639 at Nov. 30, 2005.

Cash flow for the three-month period averaged C$71,088 per month, up from the average of C$47,261 per month in the same quarter of 2005. For the nine-month period, cash flow used in operating activities averaged C$55,248 per month compared to C$52,933 during the same period of 2005.

The year-to-date net loss for the nine-month period ended Aug. 31 improved by 1% to C$567,580 or C$0.02 loss per share, from the C$573,056, or C$0.02 loss per share, during the same period in 2005.

Biophage is a biotechnology company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.